EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis

Edoardo G Giannini iD, Andrea Pasta iD, Francesco Calabrese iD, Sara Labanca iD, Simona Marenco iD, Giulia Pieri iD, Maria Corina Plaz Torres iD, Mario Strazzabosco iD

Liver International · 2025

DOI: 10.1111/liv.16222 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Liver International, 2025. Verfasst von Edoardo G Giannini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Approximately 40% of patients with Primary Biliary Cholangitis (PBC) show incomplete response to ursodeoxycholic acid, thus needing second‐line treatment to prevent disease progression. As no head‐to‐head comparison study is available, we used a network meta‐analysis (NMA) to compare efficacy and safety of available second‐line therapies.

Methods

We performed a systematic literature review including randomised, placebo‐controlled trials of patients with PBC and incomplete response, or intolerance, to ursodeoxycholic acid, and compared relative risks (RRs) for primary (biochemical response at 52‐week) and secondary outcomes [incidence of new‐onset pruritus and serious adverse events (SAEs)].

Results

The NMA included three studies, each testing obeticholic acid (OCA), seladelpar or elafibranor versus placebo (active therapy/placebo: 379/191 patients). All treatments significantly increased the RR for biochemical response with an advantage of elafibranor versus seladelpar (RR: 4.37, 95% CI: 1.01–18.87). OCA 5–10 mg/10 mg was associated with a higher risk of new‐onset pruritus compared to placebo (RR: 1.43; 95% CI: 1.09–1.88/RR: 1.79; 95% CI: 1.37–2.33), while seladelpar decreased this risk (RR: 0.30; 95% CI: 0.12–0.80). Compared to placebo, OCA 5–10 mg/10 mg was associated with an increased risk of SAE (RR: 3.82; 95% CI: 1.46–10.02/RR 2.67; 95% CI: 1.00–7.08).

Conclusions

Among second line therapies for patients with PBC, elafibranor is slightly more effective in obtaining biochemical response than seladelpar that, on the other hand, is the only drug associated with a lower incidence of pruritus. While of similar efficacy, OCA was associated with increased pruritus and SAEs. These findings may help personalise second‐line treatment in patients with PBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chenodeoxycholic AcidLiver Cirrhosis, BiliaryUrsodeoxycholic AcidRandomized Controlled Trials as TopicPruritusHumansCholagogues and CholereticsFibric AcidsTreatment OutcomeDisease ProgressionSalicylatesPhosphoric Diester HydrolasesPropionatesChalconesLysophospholipase D

Stichwörter der Autor:innen

bezafibrateelafibranorobeticholic acidresponseseladelpartreatmentursodeoxycholic acid

Substanzen

Chenodeoxycholic AcidUrsodeoxycholic AcidCholagogues and CholereticsFibric AcidsSalicylatesPhosphoric Diester HydrolasesPropionatesChalconesLysophospholipase Dobeticholic acid

Autor:innen und Institutionen

  • Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Gastroenterology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Liver Center, Digestive Diseases Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Edoardo G Giannini, Andrea Pasta, Francesco Calabrese, Sara Labanca, Simona Marenco, Giulia Pieri, Maria Corina Plaz Torres, Mario Strazzabosco

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Giannini, E. G., Pasta, A., Calabrese, F., Labanca, S., Marenco, S., Pieri, G., Plaz Torres, M. C., & Strazzabosco, M. (2025). Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis. Liver International. https://doi.org/10.1111/liv.16222

Vancouver

Giannini EG, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, et al. Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis. Liver International. 2025. doi:10.1111/liv.16222

BibTeX
@article{Giannini2025,
  author = {Giannini, Edoardo G and Pasta, Andrea and Calabrese, Francesco and Labanca, Sara and Marenco, Simona and Pieri, Giulia and Plaz Torres, Maria Corina and Strazzabosco, Mario},
  title = {Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.16222}
}
Kostenlos starten →